STOCK TITAN

[Form 4] Insmed, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

The Form 144 filing relates to a proposed sale of 2,216 MYTE common shares (approx. market value $16,287.60) through Morgan Stanley Smith Barney on or about 07 July 2025. The seller acquired the shares on 30 June 2025 via restricted stock units granted by the issuer, MYT Netherlands Parent B.V. (MYTE). A prior Rule 10b5-1 sale of 10,000 shares on 14 May 2025 for $100,457 is also disclosed. The proposed sale represents roughly 0.0016 % of the company’s 136,374,256 shares outstanding, indicating an immaterial impact on the public float. No additional financial metrics, earnings data, or corporate developments accompany the notice. The signer certifies no undisclosed material adverse information. Overall, this is a routine administrative filing signalling a minor potential insider transaction rather than a strategic corporate event.

La presentazione del modulo 144 riguarda una proposta di vendita di 2.216 azioni ordinarie MYTE (valore di mercato approssimativo di $16.287,60) tramite Morgan Stanley Smith Barney intorno al 07 luglio 2025. Il venditore ha acquisito le azioni il 30 giugno 2025 tramite unità azionarie vincolate concesse dall’emittente, MYT Netherlands Parent B.V. (MYTE). Viene inoltre comunicata una precedente vendita secondo la regola 10b5-1 di 10.000 azioni il 14 maggio 2025 per $100.457. La vendita proposta rappresenta circa lo 0,0016% delle 136.374.256 azioni in circolazione della società, indicando un impatto trascurabile sul flottante pubblico. Nessun dato finanziario aggiuntivo, risultati economici o sviluppi societari sono allegati alla notifica. Il firmatario certifica l’assenza di informazioni materiali negative non divulgate. Nel complesso, si tratta di una comunicazione amministrativa di routine che segnala una potenziale transazione interna di entità limitata piuttosto che un evento strategico aziendale.

La presentación del formulario 144 se refiere a una propuesta de venta de 2,216 acciones ordinarias MYTE (valor de mercado aproximado de $16,287.60) a través de Morgan Stanley Smith Barney alrededor del 07 de julio de 2025. El vendedor adquirió las acciones el 30 de junio de 2025 mediante unidades de acciones restringidas otorgadas por el emisor, MYT Netherlands Parent B.V. (MYTE). También se divulga una venta previa bajo la norma 10b5-1 de 10,000 acciones el 14 de mayo de 2025 por $100,457. La venta propuesta representa aproximadamente el 0.0016% de las 136,374,256 acciones en circulación de la compañía, indicando un impacto insignificante en el flotante público. No se acompañan métricas financieras adicionales, datos de ganancias ni desarrollos corporativos con el aviso. El firmante certifica que no existe información adversa material no divulgada. En general, se trata de una presentación administrativa rutinaria que señala una posible transacción interna menor más que un evento corporativo estratégico.

Form 144 제출은 2,216 MYTE 보통주 (시장 가치 약 $16,287.60)의 매각 제안과 관련되며, 이는 Morgan Stanley Smith Barney를 통해 2025년 7월 7일경 이루어질 예정입니다. 매도자는 2025년 6월 30일 발행사인 MYT Netherlands Parent B.V. (MYTE)로부터 제한 주식 단위(RSU)를 통해 해당 주식을 취득했습니다. 또한 2025년 5월 14일 10,000주를 $100,457에 매도한 Rule 10b5-1에 따른 이전 매각도 공시되었습니다. 제안된 매각은 회사의 136,374,256주 발행 주식 중 약 0.0016%에 해당하며, 공공 유통 주식에 미미한 영향을 미칩니다. 추가적인 재무 지표, 수익 데이터 또는 기업 개발 사항은 공지에 포함되어 있지 않습니다. 서명자는 공개되지 않은 중대한 부정적 정보가 없음을 인증합니다. 전반적으로 이는 전략적 기업 이벤트보다는 소규모 내부자 거래 가능성을 알리는 일상적인 행정 신고입니다.

Le dépôt du formulaire 144 concerne une proposition de vente de 2 216 actions ordinaires MYTE (valeur marchande approximative de 16 287,60 $) via Morgan Stanley Smith Barney aux alentours du 07 juillet 2025. Le vendeur a acquis les actions le 30 juin 2025 par le biais d’unités d’actions restreintes accordées par l’émetteur, MYT Netherlands Parent B.V. (MYTE). Une vente antérieure selon la règle 10b5-1 de 10 000 actions, réalisée le 14 mai 2025 pour 100 457 $, est également divulguée. La vente proposée représente environ 0,0016 % des 136 374 256 actions en circulation de la société, indiquant un impact négligeable sur le flottant public. Aucun autre indicateur financier, donnée sur les résultats ou développement d’entreprise n’accompagne la notification. Le signataire certifie l’absence d’informations défavorables importantes non divulguées. Dans l’ensemble, il s’agit d’un dépôt administratif de routine signalant une transaction interne potentielle mineure plutôt qu’un événement stratégique d’entreprise.

Die Form 144-Einreichung bezieht sich auf einen geplanten Verkauf von 2.216 MYTE-Stammaktien (ungefährer Marktwert $16.287,60) über Morgan Stanley Smith Barney etwa am 07. Juli 2025. Der Verkäufer erwarb die Aktien am 30. Juni 2025 durch eingeschränkte Aktieneinheiten, die vom Emittenten MYT Netherlands Parent B.V. (MYTE) gewährt wurden. Ebenfalls offengelegt wird ein vorheriger Verkauf von 10.000 Aktien am 14. Mai 2025 gemäß Regel 10b5-1 für $100.457. Der geplante Verkauf entspricht etwa 0,0016% der 136.374.256 ausstehenden Aktien des Unternehmens und hat somit eine unerhebliche Auswirkung auf den Streubesitz. Es werden keine weiteren finanziellen Kennzahlen, Gewinnzahlen oder Unternehmensentwicklungen mitgeteilt. Der Unterzeichner bestätigt, dass keine nicht offengelegten wesentlichen negativen Informationen vorliegen. Insgesamt handelt es sich um eine routinemäßige administrative Meldung, die auf eine kleinere potenzielle Insidertransaktion hinweist, nicht jedoch auf ein strategisches Unternehmensereignis.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: 2,216-share Form 144 sale; negligible at 0.0016 % float—insider activity immaterial to valuation.

The filing authorises the resale of 2,216 MYTE shares, valued at only $16k, versus a >136 million share count. Such volume will not alter supply-demand dynamics nor signal a major shift in insider sentiment, especially given the shares were recently vested RSUs. Investors typically monitor larger clustered sales or programmatic 10b5-1 activity; here, the prior 10,000-share May sale (£100k) is still a fraction of float. I view the disclosure as neutral; it neither improves nor worsens the investment thesis.

TL;DR: Routine compliance filing; confirms seller’s Rule 10b5-1 certification, no red flags spotted.

The notice reiterates standard certifications: absence of undisclosed adverse information and acknowledgment of criminal liability for misstatements. Inclusion of the 10b5-1 plan date maintains transparency. No accelerated or concentrated disposals are evident. Therefore, governance risk remains unchanged, and investors should treat this as ordinary course compliance.

La presentazione del modulo 144 riguarda una proposta di vendita di 2.216 azioni ordinarie MYTE (valore di mercato approssimativo di $16.287,60) tramite Morgan Stanley Smith Barney intorno al 07 luglio 2025. Il venditore ha acquisito le azioni il 30 giugno 2025 tramite unità azionarie vincolate concesse dall’emittente, MYT Netherlands Parent B.V. (MYTE). Viene inoltre comunicata una precedente vendita secondo la regola 10b5-1 di 10.000 azioni il 14 maggio 2025 per $100.457. La vendita proposta rappresenta circa lo 0,0016% delle 136.374.256 azioni in circolazione della società, indicando un impatto trascurabile sul flottante pubblico. Nessun dato finanziario aggiuntivo, risultati economici o sviluppi societari sono allegati alla notifica. Il firmatario certifica l’assenza di informazioni materiali negative non divulgate. Nel complesso, si tratta di una comunicazione amministrativa di routine che segnala una potenziale transazione interna di entità limitata piuttosto che un evento strategico aziendale.

La presentación del formulario 144 se refiere a una propuesta de venta de 2,216 acciones ordinarias MYTE (valor de mercado aproximado de $16,287.60) a través de Morgan Stanley Smith Barney alrededor del 07 de julio de 2025. El vendedor adquirió las acciones el 30 de junio de 2025 mediante unidades de acciones restringidas otorgadas por el emisor, MYT Netherlands Parent B.V. (MYTE). También se divulga una venta previa bajo la norma 10b5-1 de 10,000 acciones el 14 de mayo de 2025 por $100,457. La venta propuesta representa aproximadamente el 0.0016% de las 136,374,256 acciones en circulación de la compañía, indicando un impacto insignificante en el flotante público. No se acompañan métricas financieras adicionales, datos de ganancias ni desarrollos corporativos con el aviso. El firmante certifica que no existe información adversa material no divulgada. En general, se trata de una presentación administrativa rutinaria que señala una posible transacción interna menor más que un evento corporativo estratégico.

Form 144 제출은 2,216 MYTE 보통주 (시장 가치 약 $16,287.60)의 매각 제안과 관련되며, 이는 Morgan Stanley Smith Barney를 통해 2025년 7월 7일경 이루어질 예정입니다. 매도자는 2025년 6월 30일 발행사인 MYT Netherlands Parent B.V. (MYTE)로부터 제한 주식 단위(RSU)를 통해 해당 주식을 취득했습니다. 또한 2025년 5월 14일 10,000주를 $100,457에 매도한 Rule 10b5-1에 따른 이전 매각도 공시되었습니다. 제안된 매각은 회사의 136,374,256주 발행 주식 중 약 0.0016%에 해당하며, 공공 유통 주식에 미미한 영향을 미칩니다. 추가적인 재무 지표, 수익 데이터 또는 기업 개발 사항은 공지에 포함되어 있지 않습니다. 서명자는 공개되지 않은 중대한 부정적 정보가 없음을 인증합니다. 전반적으로 이는 전략적 기업 이벤트보다는 소규모 내부자 거래 가능성을 알리는 일상적인 행정 신고입니다.

Le dépôt du formulaire 144 concerne une proposition de vente de 2 216 actions ordinaires MYTE (valeur marchande approximative de 16 287,60 $) via Morgan Stanley Smith Barney aux alentours du 07 juillet 2025. Le vendeur a acquis les actions le 30 juin 2025 par le biais d’unités d’actions restreintes accordées par l’émetteur, MYT Netherlands Parent B.V. (MYTE). Une vente antérieure selon la règle 10b5-1 de 10 000 actions, réalisée le 14 mai 2025 pour 100 457 $, est également divulguée. La vente proposée représente environ 0,0016 % des 136 374 256 actions en circulation de la société, indiquant un impact négligeable sur le flottant public. Aucun autre indicateur financier, donnée sur les résultats ou développement d’entreprise n’accompagne la notification. Le signataire certifie l’absence d’informations défavorables importantes non divulguées. Dans l’ensemble, il s’agit d’un dépôt administratif de routine signalant une transaction interne potentielle mineure plutôt qu’un événement stratégique d’entreprise.

Die Form 144-Einreichung bezieht sich auf einen geplanten Verkauf von 2.216 MYTE-Stammaktien (ungefährer Marktwert $16.287,60) über Morgan Stanley Smith Barney etwa am 07. Juli 2025. Der Verkäufer erwarb die Aktien am 30. Juni 2025 durch eingeschränkte Aktieneinheiten, die vom Emittenten MYT Netherlands Parent B.V. (MYTE) gewährt wurden. Ebenfalls offengelegt wird ein vorheriger Verkauf von 10.000 Aktien am 14. Mai 2025 gemäß Regel 10b5-1 für $100.457. Der geplante Verkauf entspricht etwa 0,0016% der 136.374.256 ausstehenden Aktien des Unternehmens und hat somit eine unerhebliche Auswirkung auf den Streubesitz. Es werden keine weiteren finanziellen Kennzahlen, Gewinnzahlen oder Unternehmensentwicklungen mitgeteilt. Der Unterzeichner bestätigt, dass keine nicht offengelegten wesentlichen negativen Informationen vorliegen. Insgesamt handelt es sich um eine routinemäßige administrative Meldung, die auf eine kleinere potenzielle Insidertransaktion hinweist, nicht jedoch auf ein strategisches Unternehmensereignis.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bonstein Sara

(Last) (First) (Middle)
700 US HIGHWAY 202/206

(Street)
BRIDGEWATER NJ 08807

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INSMED Inc [ INSM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/07/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/07/2025 M(1) 6,244 A $19.74 100,137(2) D
Common Stock 07/07/2025 M(1) 4,362 A $24.7 104,499 D
Common Stock 07/07/2025 M(1) 23,565 A $26.43 128,064 D
Common Stock 07/07/2025 M(1) 13,717 A $26.46 141,781 D
Common Stock 07/07/2025 S(1) 35,583 D $95.66(3) 106,198 D
Common Stock 07/07/2025 S(1) 22,181 D $96.19(4) 84,017 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $19.74 07/07/2025 M(1) 6,244 (5) 01/05/2033 Common Stock 6,244 $0 18,880 D
Stock Option (right to buy) $24.7 07/07/2025 M(1) 4,362 (6) 05/12/2030 Common Stock 4,362 $0 0 D
Stock Option (right to buy) $26.43 07/07/2025 M(1) 23,565 (5) 01/06/2032 Common Stock 23,565 $0 15,710 D
Stock Option (right to buy) $26.46 07/07/2025 M(1) 13,717 (6) 05/12/2031 Common Stock 13,717 $0 12,023 D
Explanation of Responses:
1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 5, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
2. Includes 357 shares acquired through the Company's 2018 Employee Stock Purchase Plan.
3. This is the weighted average sales price representing 35,583 shares sold at prices ranging from $95.01 to $96.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
4. This is the weighted average sales price representing 22,181 shares sold at prices ranging from $96.01 to $96.95 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
5. The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
6. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
Remarks:
/s/ Sara Bonstein, by Michael A. Smith as Attorney-in-fact 07/09/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MYTE shares are being sold under this Form 144?

The notice covers 2,216 common shares of MYT Netherlands Parent B.V.

What is the approximate market value of the proposed MYTE share sale?

The aggregate market value is $16,287.60.

When is the MYTE share sale expected to occur?

The filing lists an approximate sale date of 07/09/2025.

What percentage of MYTE’s outstanding shares does the sale represent?

It represents roughly 0.0016 % of the 136,374,256 shares outstanding.

Were there any other recent insider sales disclosed?

Yes, a 10b5-1 sale of 10,000 shares on 05/14/2025 generating $100,457 is disclosed.

Which broker is handling the transaction?

Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.
Insmed Inc

NASDAQ:INSM

INSM Rankings

INSM Latest News

INSM Latest SEC Filings

INSM Stock Data

18.58B
187.30M
0.98%
112.55%
8.07%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER